News & Updates

Internal guidelines, pharmacokinetic consultation improve vancomycin therapy

17 Jun 2021

A study has shown that implementing internal guidelines and a pharmacokinetic (PK) consultation service leads to a significant improvement in use of vancomycin and, consequently, patient safety.

Internal guidelines, pharmacokinetic consultation improve vancomycin therapy

17 Jun 2021

Atorvastatin: Is there evidence of benefit in COVID-19?

17 Jun 2021 by

Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.

Atorvastatin: Is there evidence of benefit in COVID-19?

17 Jun 2021

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021 by

The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

17 Jun 2021

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021 by

Patients with psoriasis may be at an increased risk of contracting COVID-19, according to a study presented at AAD VMX 2021.

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

16 Jun 2021

COPD tied to excess death risk, even in younger adults

15 Jun 2021 by

Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.

COPD tied to excess death risk, even in younger adults

15 Jun 2021

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

The fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia (CABP), regardless of body mass index (BMI), according to a phase III trial.

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

15 Jun 2021

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021 by

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

PAP-treated sleep apnoea tied to reduced COVID-19 risk

14 Jun 2021

Regional variations in prevalence, hidden reservoir sustain malaria in Myanmar

14 Jun 2021

Though the overall disease prevalence is low, transmission of malaria varies widely across villages in Myanmar, a recent study has found. Compounding this heterogeneity is a large hidden reservoir of asymptomatic Plasmodium vivax infections, which further complicates disease elimination.

Regional variations in prevalence, hidden reservoir sustain malaria in Myanmar

14 Jun 2021

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021 by

In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

13 Jun 2021

Antibody cocktail cuts hospitalization, death in COVID-19

12 Jun 2021 by

The REGN-COV2 monoclonal antibody cocktail comprising casirivimab and imdevimab significantly reduces the risk of hospitalization and all-cause death by 71 percent compared with placebo in nonhospitalized patients with COVID-19, according to a large phase III study presented at the ATS 2021 Meeting.

Antibody cocktail cuts hospitalization, death in COVID-19

12 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Internal guidelines, pharmacokinetic consultation improve vancomycin therapy

Internal guidelines, pharmacokinetic consultation improve vancomycin therapy

Atorvastatin: Is there evidence of benefit in COVID-19?

Atorvastatin: Is there evidence of benefit in COVID-19?

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

Psoriasis may up COVID-19 risk, effect of biologic treatment on risk varies

COPD tied to excess death risk, even in younger adults

COPD tied to excess death risk, even in younger adults

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

BMI does not modify safety, efficacy of fixed-dose omadacycline for CABP

PAP-treated sleep apnoea tied to reduced COVID-19 risk

PAP-treated sleep apnoea tied to reduced COVID-19 risk

Regional variations in prevalence, hidden reservoir sustain malaria in Myanmar

Regional variations in prevalence, hidden reservoir sustain malaria in Myanmar

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Therapeutic rivaroxaban for stable COVID-19: More risk than benefit

Antibody cocktail cuts hospitalization, death in COVID-19

Antibody cocktail cuts hospitalization, death in COVID-19